{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:22:51Z","timestamp":1770438171390,"version":"3.49.0"},"reference-count":23,"publisher":"S. Karger AG","issue":"1-2","license":[{"start":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T00:00:00Z","timestamp":1378425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T00:00:00Z","timestamp":1378425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron Clin Pract"],"abstract":"<b><i>Background:<\/i><\/b> The role of the mammalian target of rapamycin (mTOR) inhibition in the treatment of autosomal dominant polycystic kidney disease (ADPKD) remains unclear. This meta-analysis included all randomized controlled trials (RCTs) that used mTOR inhibitors (TORIs) to halt the progression of ADPKD. <b><i>Methods:<\/i><\/b> Databases including MEDLINE, EMBASE, and the Cochrane Library were searched to find relevant trials. RCTs of TORI treatment in patients with ADPKD were included. Effects on the primary outcome [total kidney volume (TKV)] and secondary outcomes [changes in cyst volume (CV) and parenchymal volume (PV), glomerular filtration rate (GFR), proteinuria, and adverse events] were analyzed. <b><i>Results:<\/i><\/b> The results of 5 RCTs, which included 619 patients, were analyzed. TORIs did not significantly reduce TKV [mean difference (WMD) -90.01 ml, 95% CI -235.49 to 55.47, p = 0.23; I<sup>2<\/sup> = 0%; p for heterogeneity = 0.67]. CV decreased after TORI treatment (WMD -15.08 ml, 95% CI -17.82 to -12.34, p < 0.00001), and PV did not change (WMD -0.55 ml, 95% CI -64.55 to 63.45, p = 0.99). There was no significant difference in GFR between the TORI-treated and control groups (WMD 4.94 ml\/min, 95% CI -0.81 to 10.68, p = 0.09). Proteinuria was significantly higher in the TORI-treated group than in the control group (standard mean difference 0.27, 95% CI 0.09-0.44, p = 0.002). <b><i>Conclusion:<\/i><\/b> Long-term treatment with TORIs does not benefit patients with ADPKD.<\/jats:p>","DOI":"10.1159\/000354398","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T08:05:20Z","timestamp":1378368320000},"page":"10-16","source":"Crossref","is-referenced-by-count":15,"title":["Long-Term Treatment with Mammalian Target of Rapamycin Inhibitor Does Not Benefit Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-Analysis"],"prefix":"10.1159","volume":"124","author":[{"given":"Cheng","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2013,9,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMcp0804458"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2807%2960601-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2215%2FCJN.00330705"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.0509694103"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfi181"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2004080660"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2007050626"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038%2Fnrd2062"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa1003491"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0907419"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2009121302"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.transproceed.2012.06.073"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfs264"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2215%2FCJN.00550110"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2215%2FCJN.01360210"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI28984"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2012040367"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159%2F000104818"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007%2Fs10157-012-0706-3"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097%2F01.tp.0000228921.43200.f7"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097%2FTP.0b013e3181927a41"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1600-6143.2008.02272.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016%2FS0895-4356%2801%2900414-0"}],"container-title":["Nephron Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/354398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/354398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:44:45Z","timestamp":1745433885000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000354398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,6]]},"references-count":23,"journal-issue":{"issue":"1-2","published-online":{"date-parts":[[2013,12,1]]},"published-print":{"date-parts":[[2013,12,4]]}},"URL":"https:\/\/doi.org\/10.1159\/000354398","archive":["Portico"],"relation":{},"ISSN":["1660-2110"],"issn-type":[{"value":"1660-2110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,6]]}}}